Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
colorectal cancer
Biotech
ESMO: Exelixis' TKI reduces risk of death by 20%
The company believes the data for zanzalintinib validate its hopes of having another “franchise molecule” on its hands.
James Waldron
Oct 20, 2025 2:30am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Olympus launches AI for spotting polyps in colonoscopy
Sep 30, 2025 11:30am
CytomX reports patient death from kidney injury in ADC trial
Aug 14, 2025 6:45am
Gilead hands back one Arcus cancer candidate from $725M deal
Aug 7, 2025 6:35am
Cosmo to connect Medtronic GI Genius with Apple Vision Pro
Jun 25, 2025 4:00pm
